Please login to the form below

Not currently logged in

Hans Lennernas joins board of CMO Recipharm

He is currently professor of biopharmaceuticals at Uppsala University

Sweden-based contract manufacturing organisation (CMO) Recipharm has appointed Professor Hans Lennernäs to its board of directors.

Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of oral drugs.

Other industry experience includes serving as principle investigator in a collaborative project between US drug regulator the FDA, the University of Michigan and the Medical Product Agency in Sweden to develop a new guideline for the biopharmaceuticals classification systems.

Prof Lennernäs has also helped to launch several life sciences companies, including DuoCort Pharma and LIDDS.

“We are very pleased to welcome a board member of Hans Lennernäs calibre,” said Maria Lundberg, manager of Recipharm, which supplies pharma companies with products such as solid dose medicines, granulates and powders, sterile liquids and lyophilisates, hormones, oral liquids, sprays and dry powder inhalers.

“His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the board.”

6th February 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...